Chembio Diagnostics develops and commercializes point-of-care diagnostic tests used for the detection and diagnosis of infectious diseases, including sexually transmitted disease and COVID-19. Co.'s product portfolio is based upon its proprietary DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the diagnostic test market, which includes infectious diseases, cardiac markers, cholesterol and lipids, and drugs of abuse. The DPP technology platform can provide sensitivity and specificity, multiplexing capabilities, and with the DPP Micro Reader, quantitative results. We show 48 historical shares outstanding datapoints in our coverage of CEMI's shares outstanding history.
Understanding the changing numbers of CEMI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CEMI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CEMI by allowing them to research CEMI shares outstanding history
as well as any other stock in our coverage universe. |
Free CEMI Email Alerts:
Video: Shares Outstanding Importance
